Invention Grant
US09273131B2 Anti-bFGF humanized double-stranded antibody with stable disulfide bond, preparation method and application thereof
有权
具有稳定二硫键的抗bFGF人源化双链抗体,其制备方法和应用
- Patent Title: Anti-bFGF humanized double-stranded antibody with stable disulfide bond, preparation method and application thereof
- Patent Title (中): 具有稳定二硫键的抗bFGF人源化双链抗体,其制备方法和应用
-
Application No.: US14369363Application Date: 2012-08-20
-
Publication No.: US09273131B2Publication Date: 2016-03-01
- Inventor: Ning Deng , Haowu Jiang , Zhongkui Kang , Hong Wang , Qifang Song
- Applicant: Ning Deng , Haowu Jiang , Zhongkui Kang , Hong Wang , Qifang Song
- Applicant Address: CN
- Assignee: Jinan University
- Current Assignee: Jinan University
- Current Assignee Address: CN
- Agency: Lerner, David, Littenberg, Krumholz & Mentlik, LLP
- Priority: CN201110450855 20111228
- International Application: PCT/CN2012/080357 WO 20120820
- International Announcement: WO2013/097470 WO 20130704
- Main IPC: C07K16/22
- IPC: C07K16/22 ; A61K39/395 ; C12N15/66

Abstract:
Disclosed are an anti-bFGF humanized double-stranded antibody with stable disulfide bond, the preparation method and the applications thereof. The amino acid sequence of the anti-bFGF humanized ds-Diabody is shown in SEQ ID NO.1. The nucleotide sequence of gene encoding the anti-bFGF humanized ds-Diabody is shown in SEQ ID NO.2. By site-directed mutation, two cysteine residues are introduced into VL and VH domain of anti-bFGF Diabody, thus introducing the disulfide bond and form ds-Diabody. It is shown by experiments that the obtained ds-Diabody has the following advantages: enhanced stability; better affinity when binding to the specific antigen bFGF; moderate relative molecular weight, good tumor targeting, more powerful in tumor tissue penetration, and higher blood clearance rate, showing a broad application prospects in the clinic diagnosis and tumor therapy.
Public/Granted literature
Information query